Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies
Lupus Science & Medicine · 2024
DOI: 10.1136/lupus-2023-001068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lupus Science & Medicine, 2024. Verfasst von Gabriel Figueroa-Parra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Lupus Nephritis, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Objective
We aimed to evaluate the robustness of phase III randomised controlled trials (RCTs) for SLE and lupus nephritis (LN) using the fragility index (FI), the reverse FI (RFI) and the fragility quotient (FQ).
Methods
We searched for phase III RCTs that included patients with active SLE or LN. Data on primary endpoints, total participants and the number of events for each arm were obtained. We calculated the FI score for RCTs with statistically significant results (number of patients required to change from event to non-event to make the study lose statistical significance), the RFI for RCTs without statistically significant results (number of patients required to change from non-event to event to make study gain statistical significance) and the FQ score for both (FI or RFI score divided by the sample size).
Results
We evaluated 20 RCTs (16 SLE, four LN). The mean FI/RFI score was 13.6 (SD 6.6). There were nine RCTs with statistically significant results (seven SLE, two LN), and the mean FI score was 10.2 (SD 6.2). The lowest FI was for the ILLUMINATE-2 trial (FI=2), and the highest FI was for the BLISS-52 trial (FI=17). Twelve studies had non-statistically significant results (10 SLE, two LN) with a mean RFI score of 15.6 (SD 6.1). The lowest RFI was for the ILLUMINATE-1 trial (RFI=4), and the highest RFI was for the TULIP-1 trial (RFI=27). The lowest FQ scores were found in the ILLUMINATE trials and the highest in the Rituximab trials (EXPLORER and LUNAR), meaning that the last ones were the most robust results after accounting for sample size.
Conclusions
The evidence of therapies for patients with SLE and LN is derived mostly from fragile RCTs. Clinicians and trialists must be aware of the fragility of these RCTs for clinical decision-making and designing trials for novel therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Rheumatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA duarte.ali@mayo.edu.
- Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Gabriel Figueroa-Parra, Alí Duarte-García
Förderung
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
Zitieren
APA
Figueroa-Parra, G., Putman, M. S., Crowson, C. S., & Duarte-García, A. (2024). Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies. Lupus Science & Medicine. https://doi.org/10.1136/lupus-2023-001068
Vancouver
Figueroa-Parra G, Putman MS, Crowson CS, Duarte-García A. Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies. Lupus Science & Medicine. 2024. doi:10.1136/lupus-2023-001068
BibTeX
@article{FigueroaParra2024,
author = {Figueroa-Parra, Gabriel and Putman, Michael S and Crowson, Cynthia S and Duarte-García, Alí},
title = {Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies},
journal = {Lupus Science & Medicine},
year = {2024},
doi = {10.1136/lupus-2023-001068}
}
EUVIMED